MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+32.51%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$427M
AUM Growth
+$427M
(+14%)
Cap. Flow
-$7.07M
Cap. Flow
% of AUM
-1.65%
Top 10 Holdings %
Top 10 Hldgs %
60.67%
Holding
34
New
2
Increased
10
Reduced
13
Closed
2
Top Buys
| 1 |
ALX Oncology
ALXO
|
$18.8M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$3.57M |
| 3 |
Disc Medicine
IRON
|
$2.89M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
$23.3K |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$21.8K |
Top Sells
| 1 |
Relay Therapeutics
RLAY
|
$5.73M |
| 2 |
KalVista Pharmaceuticals
KALV
|
$5.57M |
| 3 |
Travere Therapeutics
TVTX
|
$4.94M |
| 4 |
Intellia Therapeutics
NTLA
|
$4.94M |
| 5 |
Viridian Therapeutics
VRDN
|
$3.38M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Viking Therapeutics
VKTX
$3.02B
| $6.05M | 1.42% |
325,284
+284
| +0.1% | +$5.29K |
|
|
ADAP
27
Adaptimmune Therapeutics
ADAP
$13.9M
| $4.04M | 0.95% |
5,095,912
| – | – |
|
|
HARP
28
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $3.63M | 0.85% |
319,670
| – | – |
|
|
29
Disc Medicine
IRON
$2.14B
| $2.89M | 0.68% |
+50,000
| New | +$2.89M |
|
|
30
Viridian Therapeutics
VRDN
$1.59B
| $2.18M | 0.51% |
100,000
-155,323
| -61% | -$3.38M |
|
|
INZY
31
DELISTED
Inozyme Pharma
INZY
| $1.38M | 0.32% |
323,813
-3,108
| -1% | -$13.2K |
|
32
Phathom Pharmaceuticals
PHAT
$843M
| $639K | 0.15% |
70,000
-277,332
| -80% | -$2.53M |
|
|
33
Travere Therapeutics
TVTX
$1.75B
| – | – |
-552,846
| Closed | -$4.94M |
|
|
34
KalVista Pharmaceuticals
KALV
$713M
| – | – |
-577,958
| Closed | -$5.57M |
|